![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/09\/4000-30176-1.jpg\")
<\/p>\n<\/p>\n
Trillium Therapeutics Inc. <\/strong>, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of common shares of the Company at a public offering price of US$13.00 per common share (the “Offering<\/strong>”). 11,500,000 common shares were sold in the Offering, including the full exercise by the underwriters of their option to purchase up to an additional 1,500,000 common shares.<\/p>\n The gross proceeds from the Offering were US$149,500,000, before deducting underwriting commissions and other offering expenses. The Company intends to use the net proceeds of the Offering for its ongoing and planned clinical trials for its CD47 program, including drug supply and for working capital and general corporate purposes.<\/p>\n “We would like to thank all investors who placed their trust in both our unique CD47 assets as well as Trillium people. We are committed to speedily advance our investigational program into multiple Phase 2 trials, and further drive evolution of the oncology treatment paradigm toward greater adoption of novel, ground-breaking immunotherapies,” said Dr. Jan Skvarka, Trillium’s President and Chief Executive Officer.<\/p>\n Cowen and Evercore ISI acted as joint book-running managers for the Offering. JMP Securities acted as the lead manager and Ladenburg Thalmann and JonesTrading acted as co-managers for the Offering.<\/p>\n About Trillium Therapeutics:<\/strong><\/p>\n Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.<\/p>\n For more information visit: www.trilliumtherapeutics.com.<\/p>\n Contact:<\/strong> Media Contact:<\/strong> Tags:<\/b> James Parsons
James Parsons
Chief Financial Officer
Trillium Therapeutics Inc.
416-595-0627 x232
james@trilliumtherapeutics.com
http:\/\/www.trilliumtherapeutics.com\/<\/p>\n
Mike Beyer
Sam Brown Inc.
312-961-2502
mikebeyer@sambrown.com<\/p>\nSee Campaign: <\/strong>http:\/\/www.trilliumtherapeutics.com<\/a>
Contact Information:<\/b>
James Parsons
\nChief Financial Officer
\nTrillium Therapeutics Inc.
\n416-595-0627 x232
\njames@trilliumtherapeutics.com<\/p>\n
<\/a>, Wire<\/a>, Disclosure Newswire<\/a>, United States<\/a>, English<\/a><\/p>\n<\/div>\n
\nContact Information:<\/h3>\n
\nChief Financial Officer
\nTrillium Therapeutics Inc.
\n416-595-0627 x232
\njames@trilliumtherapeutics.com<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of common shares of the Company at a public offering price of US$13.00 per common share (the “Offering”). 11,500,000 common shares were sold in the Offering, including … Continue reading Trillium Closes US$150 Million Public Offering of Common Shares<\/span><\/a> Continue Reading